Avanza Fonder AB Acquires Shares of 5,151 Astera Labs, Inc. $ALAB

Avanza Fonder AB bought a new position in Astera Labs, Inc. (NASDAQ:ALAB) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,151 shares of the company’s stock, valued at approximately $857,000.

Other institutional investors have also modified their holdings of the company. Geneva Partners LLC purchased a new position in shares of Astera Labs in the 3rd quarter valued at $1,876,000. Numerai GP LLC raised its position in shares of Astera Labs by 153.1% in the 3rd quarter. Numerai GP LLC now owns 13,212 shares of the company’s stock worth $2,587,000 after acquiring an additional 7,992 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Astera Labs by 289.5% during the 3rd quarter. Handelsbanken Fonder AB now owns 126,200 shares of the company’s stock worth $24,710,000 after purchasing an additional 93,800 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Astera Labs during the 2nd quarter worth $543,000. Finally, Paragon Advisors LLC bought a new stake in Astera Labs during the third quarter valued at about $1,829,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Astera Labs Price Performance

Shares of NASDAQ:ALAB opened at $121.76 on Wednesday. The business’s 50-day moving average is $141.95 and its 200 day moving average is $165.11. Astera Labs, Inc. has a 1 year low of $47.13 and a 1 year high of $262.90. The firm has a market capitalization of $20.85 billion, a P/E ratio of 99.80, a P/E/G ratio of 2.44 and a beta of 1.74.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The business had revenue of $270.58 million during the quarter, compared to the consensus estimate of $249.46 million. During the same quarter last year, the company earned $0.37 earnings per share. The company’s quarterly revenue was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current year.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Company benefits from robust AI infrastructure demand — management/product roadmaps (Scorpio, Aries, Taurus) and hyperscaler spend are cited as growth drivers for 2026, supporting revenue momentum and longer‑term upside. ALAB Benefits From Strong AI Infrastructure Demand: What’s Ahead?
• Positive Sentiment: Index inclusion and a new shelf filing improve the stock’s public market profile — FTSE All‑World inclusion can create passive fund flows, while a shelf gives management optionality to raise capital if needed. Astera Labs Index Entry And Shelf Filing Shape Capital Access Story
• Neutral Sentiment: Management presented at the Roth conference — the transcript provides additional detail on strategy and product roadmap but contains no new market‑moving surprises. Astera Labs, Inc. (ALAB) Presents at The 38th Annual Roth Conference Transcript
• Neutral Sentiment: Market writeups explaining today’s dip summarize mixed technicals/valuation and short‑term profit‑taking rather than a single fundamental shock. Why Astera Labs, Inc. (ALAB) Dipped More Than Broader Market Today
• Negative Sentiment: Short interest has risen materially (reported ~13.5M shares as of Mar. 13, ~9.1% of shares sold short, ~2.8 days to cover) — higher short positioning increases downside pressure and volatility on negative news or further technical selling.
• Negative Sentiment: Analyst/commentary pieces flag a recent pullback and question near‑term valuation after a strong prior run; that bearish tone can reinforce selling among momentum traders. Is It Too Early To Reconsider Astera Labs (ALAB) After Recent Share Price Pullback

Wall Street Analysts Forecast Growth

ALAB has been the topic of several analyst reports. Barclays set a $165.00 target price on Astera Labs in a research note on Thursday, January 15th. Citigroup lowered their price target on shares of Astera Labs from $275.00 to $250.00 and set a “buy” rating on the stock in a report on Wednesday, February 11th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astera Labs in a research report on Wednesday, December 3rd. Loop Capital initiated coverage on shares of Astera Labs in a research note on Thursday, March 5th. They set a “buy” rating and a $250.00 price objective for the company. Finally, Northland Securities increased their target price on shares of Astera Labs from $175.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Fifteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $202.22.

Insider Buying and Selling

In other Astera Labs news, CFO Michael Truett Tate sold 12,001 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total transaction of $1,485,843.81. Following the transaction, the chief financial officer owned 192,083 shares in the company, valued at approximately $23,781,796.23. This represents a 5.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Philip Mazzara sold 10,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $117.47, for a total transaction of $1,174,700.00. Following the completion of the transaction, the general counsel directly owned 128,084 shares of the company’s stock, valued at approximately $15,046,027.48. This represents a 7.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 384,292 shares of company stock worth $48,724,919 over the last ninety days. Company insiders own 12.50% of the company’s stock.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.